{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:30:11Z","timestamp":1768566611315,"version":"3.49.0"},"posted":{"date-parts":[[2024,8,26]]},"group-title":"Cardiovascular Medicine","reference-count":39,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,2,24]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>The diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) requires advanced imaging, precluding large-scale pre-clinical testing. Artificial intelligence (AI)-enabled transthoracic echocardiography (TTE) and electrocardiography (ECG) may provide a scalable strategy for pre-clinical monitoring.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective analysis of individuals referred for nuclear cardiac amyloid testing at Yale-New Haven Health System (YNHHS, internal cohort) and Houston Methodist Hospitals (HMH, external cohort). Deep learning models trained to discriminate ATTR-CM from age\/sex-matched controls on TTE videos (AI-Echo) and ECG images (AI-ECG) were deployed to generate study-level ATTR-CM probabilities (0-100%). Longitudinal trends in AI-derived probabilities were examined using age\/sex-adjusted linear mixed models, and their discrimination of future disease was evaluated across preclinical stages.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    Among 984 participants at YNHHS (median age 74 years, 44.3% female) and 806 at HMH (69 years, 34.5% female), 112 (11.4%) and 174 (21.6%) tested positive for ATTR-CM, respectively. Across cohorts and modalities, AI-derived ATTR-CM probabilities from 7,352 TTEs and 32,205 ECGs diverged as early as 3 years before diagnosis in cases versus controls (\n                    <jats:italic>p<\/jats:italic>\n                    <jats:sub>time(x)group interaction<\/jats:sub>\n                    <jats:italic>\u2264<\/jats:italic>\n                    0.004). Among those with both AI-Echo and AI-ECG available one-to-three years\n                    <jats:italic>before<\/jats:italic>\n                    nuclear testing (n=433 [YNHHS] and 174 [HMH]), a double-negative screen at a 0.05 threshold (164 [37.9%] and 66 [37.9%], vs all else) had 90.9% and 85.7% sensitivity (specificity of 40.3% and 41.2%), whereas a double-positive screen (78 [18.0%] and 26 [14.9%], vs all else) had 85.5% and 88.9% specificity (sensitivity of 60.6% and 42.9%).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>AI-enabled echocardiography and electrocardiography may enable scalable risk stratification of ATTR-CM during its pre-clinical course.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Abstract Figure<\/jats:title>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:label>Structured Graphical Abstract.<\/jats:label>\n                    <jats:caption>\n                      <jats:p>Artificial intelligence (AI)-enhanced interpretation of standard echocardiographic videos and electrocardiographic (ECG) images may serve as digital biomarkers of disease progression during the early pre-clinical and clinical stages of transthyretin amyloid cardiomyopathy. We show that across two geographically distinct cohorts of individuals referred for nuclear cardiac amyloid testing, cases exhibit significantly faster progression in their AI-defined probabilities in the years before nuclear cardiac amyloid testing, compared with controls, a finding that was consistent across cohorts and modalities. These findings suggest that AI-enabled echocardiography and ECG may be able to identify those at risk for ATTR-CM up to 3 years before clinical diagnosis through standard clinical pathways. AI: artificial intelligence; ATTR-CM: transthyretin amyloid cardiomyopathy; ECG: electrocardiography; TTE: transthoracic echocardiography.<\/jats:p>\n                    <\/jats:caption>\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"24312556v3_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>","DOI":"10.1101\/2024.08.25.24312556","type":"posted-content","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T12:05:21Z","timestamp":1724673921000},"source":"Crossref","is-referenced-by-count":6,"title":["Tracking the Preclinical Progression of Transthyretin Amyloid Cardiomyopathy Using Artificial Intelligence-Enabled Electrocardiography and Echocardiography"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0720","authenticated-orcid":false,"given":"Evangelos K.","family":"Oikonomou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veer","family":"Sangha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3034-0641","authenticated-orcid":false,"given":"Sumukh","family":"Vasisht Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Coppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-127X","authenticated-orcid":false,"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khurram","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2156-5962","authenticated-orcid":false,"given":"Edward J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesia","family":"Gallegos-Kattan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2348-0484","authenticated-orcid":false,"given":"Mouaz H.","family":"Al-Mallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadeer","family":"Al-Kindi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-6199","authenticated-orcid":false,"given":"Rohan","family":"Khera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025022607250556000_2024.08.25.24312556v3.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"2025022607250556000_2024.08.25.24312556v3.2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890701842988"},{"key":"2025022607250556000_2024.08.25.24312556v3.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.037"},{"key":"2025022607250556000_2024.08.25.24312556v3.4","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"2025022607250556000_2024.08.25.24312556v3.5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction","volume":"6","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2025022607250556000_2024.08.25.24312556v3.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"2025022607250556000_2024.08.25.24312556v3.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"2025022607250556000_2024.08.25.24312556v3.8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy","volume":"390","year":"2024","journal-title":"N Engl J Med"},{"key":"2025022607250556000_2024.08.25.24312556v3.9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","year":"2025","journal-title":"N Engl J Med"},{"key":"2025022607250556000_2024.08.25.24312556v3.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300757"},{"key":"2025022607250556000_2024.08.25.24312556v3.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"2025022607250556000_2024.08.25.24312556v3.12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid","volume":"389","author":"aus dem Siepen Fabian, Donal Erwan, Lairez Olivier, van der Meer Peter, Kristen Arnt V","year":"2023","journal-title":"N Engl J Med"},{"key":"2025022607250556000_2024.08.25.24312556v3.13","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years","volume":"146","year":"2022","journal-title":"Circulation"},{"key":"2025022607250556000_2024.08.25.24312556v3.14","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2589-7500(23)00265-0","article-title":"Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study","volume":"6","year":"2024","journal-title":"Lancet Digit Health"},{"key":"2025022607250556000_2024.08.25.24312556v3.15","doi-asserted-by":"crossref","unstructured":"Sangha V , Oikonomou EK , Khera R . Artificial Intelligence Applied to Electrocardiographic Images for Scalable Screening of Transthyretin Amyloid Cardiomyopathy. medRxiv. 2024. p. 2024.09.30.24314651.","DOI":"10.1101\/2024.09.30.24314651"},{"key":"2025022607250556000_2024.08.25.24312556v3.16","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S2589-7500(24)00249-8","article-title":"Artificial intelligence-guided detection of under-recognised cardiomyopathies on point-of-care cardiac ultrasonography: a multicentre study","volume":"7","year":"2025","journal-title":"Lancet Digit Health"},{"key":"2025022607250556000_2024.08.25.24312556v3.17","doi-asserted-by":"crossref","unstructured":"Holste G , Oikonomou EK , Mortazavi BJ , Wang Z , Khera R . Efficient deep learning-based automated diagnosis from echocardiography with contrastive self-supervised learning. Commun Med (Lond) 2024;4:133.","DOI":"10.1038\/s43856-024-00538-3"},{"key":"2025022607250556000_2024.08.25.24312556v3.18","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1093\/eurheartj\/ehad456","article-title":"Severe aortic stenosis detection by deep learning applied to echocardiography","volume":"44","year":"2023","journal-title":"Eur Heart J"},{"key":"2025022607250556000_2024.08.25.24312556v3.19","first-page":"e000029","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging","volume":"14","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"2025022607250556000_2024.08.25.24312556v3.20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","article-title":"Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge","volume":"304","year":"2020","journal-title":"Int J Cardiol"},{"key":"2025022607250556000_2024.08.25.24312556v3.21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamacardio.2024.0595","article-title":"A multimodal video-based AI biomarker for aortic stenosis development and progression","volume":"9","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2025022607250556000_2024.08.25.24312556v3.22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/CIRCULATIONAHA.122.062646","article-title":"Detection of Left Ventricular Systolic Dysfunction From Electrocardiographic Images","volume":"148","year":"2023","journal-title":"Circulation"},{"key":"2025022607250556000_2024.08.25.24312556v3.23","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jamia\/ocae002","article-title":"Biometric contrastive learning for data-efficient deep learning from electrocardiographic images","volume":"31","year":"2024","journal-title":"J Am Med Inform Assoc"},{"key":"2025022607250556000_2024.08.25.24312556v3.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29153-3"},{"key":"2025022607250556000_2024.08.25.24312556v3.25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/13506129.2023.2229484","article-title":"Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay","volume":"30","year":"2023","journal-title":"Amyloid"},{"key":"2025022607250556000_2024.08.25.24312556v3.26","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis","volume":"83","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025022607250556000_2024.08.25.24312556v3.27","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/eurheartj\/ehad139","article-title":"Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis","volume":"44","year":"2023","journal-title":"Eur Heart J"},{"key":"2025022607250556000_2024.08.25.24312556v3.28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.112.000132"},{"key":"2025022607250556000_2024.08.25.24312556v3.29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamacardio.2021.6059","article-title":"High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning","volume":"7","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2025022607250556000_2024.08.25.24312556v3.30","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/s41467-021-22877-8","article-title":"Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms","volume":"12","year":"2021","journal-title":"Nat Commun"},{"key":"2025022607250556000_2024.08.25.24312556v3.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.04.023"},{"key":"2025022607250556000_2024.08.25.24312556v3.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.04.010"},{"key":"2025022607250556000_2024.08.25.24312556v3.33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.17935"},{"key":"2025022607250556000_2024.08.25.24312556v3.34","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/jamacardio.2023.1525","article-title":"Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US","volume":"8","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2025022607250556000_2024.08.25.24312556v3.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.4467"},{"key":"2025022607250556000_2024.08.25.24312556v3.36","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000792"},{"key":"2025022607250556000_2024.08.25.24312556v3.37","doi-asserted-by":"crossref","unstructured":"Soman P , Garcia-Pavia P , Gillmore JD , Adams D , Conceicao I , Coelho T , et al. Rationale & design of ACT-EARLY, the acoramidis transthyretin amyloidosis prevention trial: Early detection using cardiac radionuclide imaging. J Nucl Cardiol 2024;38:101948.","DOI":"10.1016\/j.nuclcard.2024.101948"},{"key":"2025022607250556000_2024.08.25.24312556v3.38","doi-asserted-by":"crossref","unstructured":"Spencer-Bonilla G , Njoroge JN , Pearson K , Witteles RM , Aras MA , Alexander KM . Racial and ethnic disparities in transthyretin cardiac amyloidosis. Curr Cardiovasc Risk Rep 2021;15.","DOI":"10.1007\/s12170-021-00670-y"},{"key":"2025022607250556000_2024.08.25.24312556v3.39","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1093\/eurheartj\/ehae415","article-title":"Artificial intelligence-enhanced patient evaluation: bridging art and science","volume":"45","year":"2024","journal-title":"Eur Heart J"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.08.25.24312556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:10:15Z","timestamp":1768507815000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.08.25.24312556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1101\/2024.08.25.24312556","relation":{},"subject":[],"published":{"date-parts":[[2024,8,26]]},"subtype":"preprint"}}